Results 261 to 270 of about 324,759 (334)

Results Of Archaeological Testing and Plan of Work for Excavation at AZ BB:13:16(ASM)-Locus F, Tohono O'odham Indian Reservation, San Xavier District, Tucson, Arizona: Report

, 1999
Margaret Glass
openalex   +1 more source

Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study

Epilepsia Open, EarlyView.
Abstract This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2‐q13.1 duplication or deletion syndromes (15q‐DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5
Emanuele Cerulli Irelli, Adolfo Mazzeo, Marco Perulli, Georgia Ramantani, Domenica Battaglia, Irene Bagnasco, Erica Cognolato, Pasquale Striano, Susanna Negrin, Alberto Danieli, Paolo Bonanni, Francesca F. Operto, Carlo Di Bonaventura, Antonietta Coppola, Alessandro Orsini   +14 more
wiley   +1 more source

Integrating GPCR Regulation and Calcium Dynamics in Airway Smooth Muscle Function: A Comprehensive Review. [PDF]

Cells
Roy S, Gangipangi VK, Sharma P, Hancock RE, Sharma P.   +4 more
europepmc   +1 more source

ASMS research awards

Journal of the American Society for Mass Spectrometry, 2010
openaire   +1 more source

Excavations at the Mound 3 Precinct Southeast Cemetery, Las Colinas, AZ T:12:10(ASM)

, 2008
Kylie Schroeder
openalex   +1 more source

”Not always the magic bullet”—Insufficient seizure control by ketogenic dietary therapies in Glut1 Deficiency Syndrome

Epilepsia Open, EarlyView.
Abstract Objective Ketogenic dietary therapies (KDTs) are the treatment of choice for Glut1 Deficiency Syndrome (Glut1DS), providing dietary ketones as an alternative fuel to the brain and effectively controlling seizures. Recent evidence indicates insufficient seizure control in Glut1DS patients despite adequate KDT and ketosis.
Joerg Klepper, Eva Runkel, Lucia Kiesel
wiley   +1 more source

Characteristics associated with first anti-seizure medication prescribed in a cohort of adults with newly diagnosed epilepsy. [PDF]

Seizure
Blank LJ, Morgenstern R, Boockvar K, Mohamed N, Jetté N.   +4 more
europepmc   +1 more source

Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach

Epilepsia Open, EarlyView.
Abstract Objectives Dravet syndrome (DS) is a drug‐resistant developmental and epileptic encephalopathy, often requiring three or more antiseizure medications (ASMs). Consequently, the therapeutic landscape is highly complex, combining DS‐specific agents (stiripentol, STP; cannabidiol, CBD; fenfluramine, FFA), non‐specific ASMs, and non‐pharmacologic ...
J. Helen Cross, Rima Nabbout, Barry Gidal, Joseph Sullivan, Elaine Wirrell   +4 more
wiley   +1 more source

Glymphatic dysfunction as a predictor of response to lacosamide add-on therapy in drug-resistant focal epilepsy. [PDF]

Front Neurol
Lee DA, Wi JH, Lee HJ, Park KM.
europepmc   +1 more source

ILAE dietary treatments task force special report: Maternal ketogenic diet exposure in epilepsy pregnancy registries—A call to action

Epilepsia Open, EarlyView.
Abstract Ketogenic dietary therapies (KDTs) are increasingly used worldwide as a non‐pharmacological treatment for epilepsy, including among people of childbearing potential. In many cases, KDTs allow for the reduction of antiseizure medications (ASMs) and lower drug exposure during pregnancy.
Magnhild Kverneland, Valentina De Giorgis, Laura Healy, Kelly Faltersack, Tanya J. W. McDonald, Marisa Armeno, Mackenzie C. Cervenka, Anita Devlin   +7 more
wiley   +1 more source